14464-46-1 Usage
Uses
Because of its unique physical and chemical properties, crystalline silica has many uses. Commercially produced silica products include quartzite, tripoli, ganister, chert, and novaculite. Crystalline silica also occurs in nature as agate, amethyst, chalcedony, cristobalite, flint, quartz, tridymite, and, in its most common form, sand (IARC 1997). Naturally occurring silica materials are classified by end use or industry. Sand and gravel are produced almost exclusively for road building and concrete construction, depending on particle size and shape, surface texture, and porosity (IARC 1987).
Definition
Different sources of media describe the Definition of 14464-46-1 differently. You can refer to the following data:
1. A hygroscopic substance such as activated alumina, calcium chloride, silica gel, or zinc chloride. Such substances adsorb water vapor from the air and are used to maintain a dry atmosphere in containers for food packaging, chemical reagents, etc.
2. Cristobalite: a mineral form of silicon(IV) oxide, SiO2.
Safety Profile
Confirmed carcinogen with experimental carcinogenic and tumorigenic data. Poison by intratracheal route. An inhalation hazard. Human systemic effects by inhalation: cough, dyspnea, fibrosis. About twice as toxic as silica in causing sihcosis. See also other sdica entries
Potential Exposure
Cristobalite is used in the manufacture of water glass, refractories, abrasives, ceramics and enamels. Quartz is used as a mineral, natural or synthetic fiber. Tridymite is used as a filtering and insulating media and as a refractory material for furnace linings. Workers are potentially exposed to crystalline silica in such industries as granite quarrying and cutting, foundry operations; metal, coal, dentistry, painting, and nonmetallic mining; and manufacture of clay and glass products.
Carcinogenicity
Respirable crystalline silica, primarily quartz dusts occurring in industrial and occupational settings, is known to be a human carcinogen based on sufficient evidence of carcinogenicity from studies in humans. Respirable crystalline silica was first listed in the Sixth Annual Report on Carcinogens in 1991 as reasonably anticipated to be a human carcinogen based on sufficient evidence of carcinogenicity from studies in experimental animals; the listing was revised to known to be a human carcinogen in the Ninth Report on Carcinogens in 2000.
Incompatibilities
Violent reactions with powerful oxidizers: fluorine, chlorine trifluoride; manganese trioxide; oxygen difluoride, hydrogen peroxide, etc.; acetylene; ammonia.
Waste Disposal
Sanitary landfill
Check Digit Verification of cas no
The CAS Registry Mumber 14464-46-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,4,4,6 and 4 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 14464-46:
(7*1)+(6*4)+(5*4)+(4*6)+(3*4)+(2*4)+(1*6)=101
101 % 10 = 1
So 14464-46-1 is a valid CAS Registry Number.
InChI:InChI=1/H2O5Si2/c1-6(2)5-7(3)4/h1,3H
14464-46-1Relevant articles and documents
CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS
-
, (2022/03/31)
Compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to depression, major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, and bipolar disorder), cancers and eye conditions: wherein R1, , R3, and L are as defined herein.
COMPOUND FOR INHIBITING PGE2/EP4 SIGNALING TRANSDUCTION INHIBITING, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF
-
, (2022/03/14)
A compound of formula (I), a preparation method therefor, a pharmaceutical composition containing a derivative thereof, and the therapeutic uses thereof, especially inhibiting PGE2/EP4 signalling transduction and the uses thereof for treating cancer, acute or chronic pain, migraine, osteoarthritis, rheumatoid arthritis, gout, bursitis, ankylosing spondylitis, primary dysmenorrhea, tumour or arteriosclerosis.
TEMPERATURE-SENSITIVE NANO SILVER CONTROLLED-RELEASE SMART ANTIBACTERIAL COATING AND PREPARATION METHOD THEREFOR
-
, (2019/02/13)
This present invention discloses a temperature-sensitive nano-silver controlled release antibacterial coating composite, which is comprises: water, acrylic, polyurethane resin, temperature-sensitive nano-silver controlled release antibacterial agent, dispersant, curing agent, defoamer, filming additive and leveling agent. By adsorbing nano silver particles into the pores of mesoporous SiO2 modified by poly N-isopropyl acrylamide, we successfully prepared a temperature-sensitive nano-silver controlled release antibacterial agent. By adding the prepared agent to the conventional coating composite, we achieved “on-off” control of the antibacterial properties of coating composite. Through the control of temperature, the release of nano-silver in the mesoporous nano-silica of the coating film layer is controlled. This control method is not only to protect the nano-silver, but also to adjust the strength of the anti-bacterial properties according to the actual demands and improve the use-efficiency of nano silver particles. This invention is in line with the new concept of “Intelligent Age” in the 21st century.
